Table 5. Predictive factors for development of cardiac dysfunction, by randomised treatment arm.
|
12 months patients |
6 months patients |
Overall |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases (n=221) | Controls (n=992) | Odds ratios (95% CI) | Cases (n=172) | Controls (n=1044) | Odds ratios (95% CI) | Cases (n=393) | Controls (n=2036) | Odds ratios (95% CI) | |
|
Chemotherapy | |||||||||
| Taxane based | 13 (16%) | 67 (84%) | — | 10 (13%) | 67 (87%) | — | 23 (15%) | 134 (85%) | — |
| Taxane and anthracycline | 95 (17%) | 457 (83%) | 1.07 (0.57–2.02) | 68 (12%) | 486 (88%) | 0.94 (0.46–1.91) | 163 (15%) | 943 (85%) | 1.01 (0.63–1.62) |
| Anthracycline based (no taxanes) | 113 (20%) | 466 (80%) | 1.25 (0.67–2.34) | 93 (16%) | 490 (84%) | 1.27 (0.63–2.56) | 206 (18%) | 956 (82%) | 1.26 (0.79–2.00) |
|
Anthracyclines | |||||||||
| ⩽3 cycles | 81 (15%) | 442 (85%) | — | 60 (12%) | 423 (88%) | — | 141 (14%) | 865 (86%) | — |
| >3 cycles | 138 (20%) | 536 (80%) | 1.41 (1.04–1.90) | 109 (15%) | 602 (85%) | 1.28 (0.91–1.79) | 247 (18%) | 1138 (82%) | 1.33 (1.06–1.67) |
|
Baseline LVEF | |||||||||
| ⩾65% | 68 (14%) | 419 (86%) | — | 52 (10%) | 479 (90%) | — | 120 (12%) | 898 (88%) | — |
| 55 to <65% | 122 (19%) | 522 (81%) | 1.44 (1.04–1.99) | 99 (16%) | 508 (84%) | 1.80 (1.26–2.57) | 221 (18%) | 1030 (82%) | 1.61 (1.26–2.04) |
| <55% | 26 (51%) | 25 (49%) | 6.41 (3.50–11.75) | 20 (33%) | 41 (67%) | 4.49 (2.45–8.24) | 46 (41%) | 66 (59%) | 5.22 (3.42–7.95) |
|
Left-sided radiotherapy | |||||||||
| No | 140 (20%) | 568 (80%) | — | 92 (14%) | 581 (86%) | — | 232 (17%) | 1149 (83%) | — |
| Yes | 80 (16%) | 410 (84%) | 0.79 (0.59–1.07) | 77 (15%) | 449 (85%) | 1.08 (0.78–1.50) | 157 (15%) | 859 (85%) | 0.91 (0.73–1.13) |
|
BMI | |||||||||
| Low/Normal | 63 (16%) | 323 (84%) | — | 49 (13%) | 322 (87%) | — | 112 (15%) | 645 (85%) | — |
| High | 154 (19%) | 660 (81%) | 1.20 (0.87–1.65) | 122 (15%) | 709 (85%) | 1.13 (0.79–1.62) | 276 (17%) | 1369 (83%) | 1.16 (0.91–1.47) |
|
Age at diagnosis | |||||||||
| <50 years old | 50 (13%) | 337 (87%) | — | 34 (9%) | 339 (91%) | — | 84 (11%) | 676 (89%) | — |
| 50–59 years old | 71 (18%) | 316 (82%) | 1.51 (1.02–2.24) | 60 (15%) | 353 (85%) | 1.70 (1.09–2.65) | 131 (16%) | 669 (84%) | 1.58 (1.17–2.12) |
| 60–69 years old | 78 (22%) | 278 (78%) | 1.89 (1.28–2.79) | 54 (16%) | 277 (84%) | 1.94 (1.23–3.07) | 132 (19%) | 555 (81%) | 1.91 (1.42–2.57) |
| 70+years old | 22 (27%) | 61 (73%) | 2.43 (1.37–4.30) | 24 (24%) | 75 (76%) | 3.19 (1.79–5.70) | 46 (25%) | 136 (75%) | 2.72 (1.82–4.08) |
|
Ethnicity | |||||||||
| White | 184 (18%) | 815 (82%) | — | 142 (14%) | 851 (86%) | — | 326 (16%) | 1666 (84%) | — |
| Other | 11 (15%) | 63 (85%) | 0.77 (0.40–1.50) | 6 (11%) | 49 (89%) | 0.73 (0.31–1.75) | 17 (13%) | 112 (87%) | 0.78 (0.46–1.31) |
|
Reported prior use of cardiac medication | |||||||||
| No | 203 (17%) | 985 (83%) | — | 161 (14%) | 1032 (87%) | — | 364 (15%) | 2017 (85%) | — |
| Yes | 18 (72%) | 7 (28%) | 12.47 (5.14–30.25) | 11 (48%) | 12 (52%) | 5.88 (2.55–13.54) | 29 (60%) | 19 (40%) | 8.46 (4.69–15.25) |
Abbreviations: BMI=body mass index; CI=confidence interval; LVEF=left ventricular ejection fraction.
Cases=patients reporting one or more episodes of clinical cardiac dysfunction and/or low LVEF in the 12-month reporting period. Controls=patients reporting no clinical cardiac dysfunction and no low LVEF in the 12-month reporting period. Results in bold indicate significant results at the 5% level (i.e., The 95% CI not spanning 1).